The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer
Both platinum-based doublet chemotherapy (PBC) and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) prolong the survival of patients with advanced non-small cell lung cancer (NSCLC). In early studies, most patients underwent PBC as first-line treatment, but not all patients co...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Sun Yat-sen University Cancer Center
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935012/ |